267 related articles for article (PubMed ID: 10911422)
1. [Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].
Borovik R; Steiner M; Atad J; Sneiderman B; Rosenberg T; Palti S
Harefuah; 1998 Apr; 134(8):605-8, 671. PubMed ID: 10911422
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
[TBL] [Abstract][Full Text] [Related]
3. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy.
Mayerhofer K; Kucera E; Zeisler H; Speiser P; Reinthaller A; Sevelda P
Gynecol Oncol; 1997 Jan; 64(1):109-13. PubMed ID: 8995557
[TBL] [Abstract][Full Text] [Related]
4. An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer.
Piccart-Gebhart MJ; Bruning P; Gamucci T; Klijn J; Roy JA; Awada A; Kusenda Z; Van Vreckem A; Paridaens R
Semin Oncol; 1996 Oct; 23(5 Suppl 11):11-5. PubMed ID: 8893893
[TBL] [Abstract][Full Text] [Related]
5. Taxol hypersensitivity: rapid retreatment is safe and cost effective.
Olson JK; Sood AK; Sorosky JI; Anderson B; Buller RE
Gynecol Oncol; 1998 Jan; 68(1):25-8. PubMed ID: 9454655
[TBL] [Abstract][Full Text] [Related]
6. [A phase II clinical study of China-made paclitaxel in the treatment of cancer patients].
Wu H; Guan Z; Lin T
Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):148-52. PubMed ID: 10920970
[TBL] [Abstract][Full Text] [Related]
7. [Taxol].
Kühnle H
Zentralbl Gynakol; 1996; 118(10):580. PubMed ID: 8999717
[No Abstract] [Full Text] [Related]
8. One-hour paclitaxel infusions: review of safety and efficacy.
Greco FA; Thomas M; Hainsworth JD
Cancer J Sci Am; 1999; 5(3):179-91. PubMed ID: 10367176
[TBL] [Abstract][Full Text] [Related]
9. [Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion].
Noda K; Ikeda M; Kudo R; Nishiya I; Yajima A; Tanaka K; Kodama S; Takahashi T; Tokunaga A; Satoh I; Nozawa S; Taketani Y; Terashima Y; Isonishi S; Takeda Y; Nishijima M; Kuroshima Y; Fujii S; Izumi R; Tamaya T; Mori T; Okada H; Ogita S; Ozaki M; Hatae M
Gan To Kagaku Ryoho; 1996 Feb; 23(3):317-25. PubMed ID: 8712825
[TBL] [Abstract][Full Text] [Related]
10. p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen.
Gadducci A; Cianci C; Cosio S; Carnino F; Fanucchi A; Buttitta F; Conte PF; Genazzani AR
Anticancer Res; 2000; 20(6C):4793-9. PubMed ID: 11205220
[TBL] [Abstract][Full Text] [Related]
11. [Weekly paclitaxel therapy for metastatic breast cancer].
Kokufu I; Taniguchi H; Kimura F; Fukuda K; Yamamoto M; Yano T; Yamada K
Gan To Kagaku Ryoho; 2002 Feb; 29(2):221-6. PubMed ID: 11865627
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
[TBL] [Abstract][Full Text] [Related]
13. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy of ovarian and breast cancer with Taxol].
Dtsch Med Wochenschr; 1996 Dec; 121(50 Suppl):1-12. PubMed ID: 9022362
[No Abstract] [Full Text] [Related]
15. [Second-line chemotherapy with paclitaxel for ovarian cancer].
Lehoczky O; Bagaméri A; Udvary J; Pulay T
Orv Hetil; 2001 Oct; 142(42):2299-301. PubMed ID: 11760646
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
Buzdar AU; Singletary SE; Valero V; Booser DJ; Ibrahim NK; Rahman Z; Theriault RL; Walters R; Rivera E; Smith TL; Holmes FA; Hoy E; Frye DK; Manuel N; Kau SW; McNeese MD; Strom E; Thomas E; Hunt K; Ames F; Berry D; Hortobagyi GN
Clin Cancer Res; 2002 May; 8(5):1073-9. PubMed ID: 12006521
[TBL] [Abstract][Full Text] [Related]
17. [Paclitaxel (Taxol)--drug of choice in ovarian cancer].
Fishman A
Harefuah; 1996 Apr; 130(8):557-60. PubMed ID: 8765885
[No Abstract] [Full Text] [Related]
18. Paclitaxel and docetaxel in breast and ovarian cancer.
Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
[TBL] [Abstract][Full Text] [Related]
19. [Taxol--a new cytostatic drug for therapy of ovarian and breast cancer].
Meden H; Rath W; Kuhn W
Geburtshilfe Frauenheilkd; 1994 Apr; 54(4):187-93. PubMed ID: 7912212
[TBL] [Abstract][Full Text] [Related]
20. [Weekly Taxol (Paclitaxel) administration in the second-line treatment of breast cancer].
Dank M
Magy Onkol; 2002; 46(2):189-91. PubMed ID: 12202898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
